Peptide Antibody Services for Antibody Generation

About Peptide Antibody Services

Immunizing with a peptide corresponding to a specific region of a protein antigen is a popular method to develop custom antibodies. With this strategy, you only need the amino acid sequence of a predicted/selected epitope within the protein antigen, avoiding homologous regions to minimize cross reactivity with other proteins. Antigenic peptides of 10-20 amino acids in length provide optimal epitope diversity while still offering superior specificity compared to immunizing with the full length protein sequence. The peptide is usually conjugated to a carrier protein such as KLH or BSA to enhance stimulation of an immune response. Antibodies are generated against the peptide sequence and the carrier protein. Therefore, the highly specific antibodies directed against the peptide are separated by affinity purification.

Why Use Peptide Antigens for Immunization?

  • Peptide epitopes represent antigen proteins
  • Chemical synthesis yields defined epitopes
  • Lower probability of cross-reactivity
  • More flexibility in antigen selection
  • Sequence diversity and PTMs can be addressed
  • Easy to synthesize, cost-effective and stable

Applications for Antibody Services

  • Antigen design
  • Production of antigen conjugates
  • Titer determination
  • Hybridoma screening
  • Epitope mapping
  • Antibody characterization
  • Blocking peptides

JPT’s Peptide Antibody Services for Antibody Generation:

Immunogen Design

Assay Development

Antibody Characterization

Process Optimization

  • Peptides as assay control
  • Affinity Purification

Selected References for Antibody Services

"Serological Profiling of the EBV Immune Response in Chronic Fatigue Syndrome Using a Peptide Microarray"
Loebel et a.l, PLoS One (2017)
"Identification of Broadly Neutralizing Monoclonal Antibodies Against Crimean-Congo Hemorrhagic Fever Virus"
Zivcec et al., Antiviral Res. (2017)
"Therapeutic Anti-IgE Monoclonal Antibody Single Chain Variable Fragment (scFv) Safety and Immunomodulatory Effects After One Time Injection in Four Dogs"
Hammerberg et al., Veterinary Dermatology (2016)
"Peptidomimetic Therapeutics: Scientific Approaches and Opportunities"
Qvit et al., Drug Discov Today (2016)
"Quantification of the Epitope Diversity of HIV-1-Specific Binding Antibodies by Peptide Microarrays for Global HIV-1 Vaccine Development"
Stephenson et al., J Immunol Methods (2015)
"Human Adenosine A2A Receptor Binds Calmodulin with High Affinity in a Calcium- Dependent Manner Identification of Protective Linear B-cell Epitopes on the Subolesin/Akirin Orthologues of Ornithodoros spp. Soft Ticks"
Manzano-Román et al., Vaccine (2015)

Read More references



Application Notes for Antibody Services

"Comprehensive Characterization of Antibodies Directed towards Epigenetic Histone‐ Modifications"
Masch et al., Application Note (2015)
"Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic Antibody IMAB362"
Daneschdar et al., Application Note (2014)
"A Modular Approach for Epitope Discovery and High‐Resolution Profiling of Humoral Immune Responses"
Pawlowski et al., Application Note (2013)
"BioTides™ as High Throughput Screening Tool for the Identification of Antibody Binding Sites"
Kühne et al., Application Note (2012)

Read More references



Application Notes for Antibody Services (copy 1)

"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT’s PepStar™ microarray technology has been very useful for the correlation of the clinical outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!"
J. Currier, PhD (Walter Reed Army Institute, Rockville, Maryland, USA)

Read More references



Check our list of products,
click and go.

News Highlights

--> Read more News

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!